Mark Kline, Ph.D.

  • Chief Technology Officer,
    Co-founder

Xiaoxi Wei, Ph.D.

  • Chief Executive Officer,
    Co-Founder

jim-greenwoodJim Greenwood

  • Board of Advisors

Board Member

Mark Kline, Ph.D.

  • Chief Technology Officer,
    Co-founder

Xiaoxi Wei, Ph.D.

  • Chief Executive Officer,
    Co-Founder

zuckermanJohannes Weggemann

  •  CFA; Managing Director/Board of Director of LOREA AG

Chemistry Advisor

zuckerman
Ronald N. Zuckermann, Ph.D.

  • Facility Director, and User Program Sr. Advisor, Lawrence Berkeley National Laboratory. Dr. Zuckermann is a world class expert in combinatorial and biomimetic chemistry with over 130 publications and 37 patents. He is providing in-house scientific advice to X-Therma.

Biology Advisors

kenneth_storey-square
Kenneth Storey, Ph.D.

  • Canada Research Chair in Molecular Physiology and Professor of Biochemistry at Carleton University, Canada. World’s leading expert in hibernation and biological stasis and creator of new approaches to gene therapy that allow organisms to survive extreme frozen states. Advisor to European and Japanese Space Agencies.

john-schloendorn
John Schloendorn, Ph.D.

  • Founder and CEO of Gene and Cell Technologies. Previously, CEO of ImmunePath, a venture capital backed regenerative medicine startup where he oversaw the development of immune cell therapies from embryonic stem cells (2009 to 2012). Director of SENS Foundation’s intramural Research Center 2006 to 2009.

Medical Advisors

gerald-brandacher
Gerald Brandacher, M.D.

  • Scientific Director, John Hopkins Reconstructive Transplantation Program; Director, Vascularized Composite Allotransplantation (VCA) Research Laboratory; Associate Professor of Surgery and of Plastic and Reconstructive Surgery at Johns Hopkins University School of Medicine. World renowned expert in VCA transplantation.


David H. Ledbetter, Ph.D., FACMG

  • Geisinger’s Executive Vice President & Chief Scientific Officer, a leading healthcare system and genomic clinical institute on Precision Medicine Initiative. Previously, he was the Robert W. Woodruff Professor and Director of the Division of Medical Genetics, Emory University School of Medicine, and held academic and leadership positions at the University of Chicago, the National Center for Human Genome Research (now NHGRI) at NIH and Baylor College of Medicine. World renowned expert in genomics.

David C. Mulligan, MD, FACS, FAASLD, FAST

  • Professor of Transplantation and Immunology at Yale University, skilled in Liver Transplantation (especially Living Donor Liver Transplant), Kidney & Pancreas Transplantation, Hepatobiliary Surgery, and Immunology. Graduated from University of Louisville School of Medicine. Honored to build the Multiorgan Transplant Program at Mayo Clinic in Arizona from 1998-2013 with outstanding growth in all solid organ transplantation with some of the best outcomes in the US. Transforming the Multiorgan transplant program at Yale to be one of the most innovative and academic institutions where patient centered care can be met with cutting edge research and science. Recently served as President of UNOS/OPTN and Chair of the Advisory Council on Transplantation to the Secretary of HHS to lead the oversight and policy development of organ transplantation in the United States. Also served as Councilor at Large for the Board of Governors of the AASLD and Chair of the Business Practice Services Committee in addition to the Wellness Committee of the ASTS. Heavily involved in developing new policies and guidance across all organ transplantation and allocation during the COVID-19 pandemic for the safest possible outcomes for patients as well as providers.

Business Advisors

mark-klopp-mba
Mark Klopp, MBA

  • Former Board Member of the National Venture Capital Association (NVCA) and served as Chairman and founding member of the Corporate Venture Group. Former Managing Director of Eastman Ventures, a top-quartile corporate fund.

mark-klopp-mba
Rodney W. Turner, BA

  • Consultant to private and public companies, as well as private equity and venture capital groups, has served and continues to serve as a director on the boards of companies in the US and Europe; 2006 through early 2014 Vice President of Corporate Business Development for Life Technologies Corporation, served as CEO of AYOXXA Biosystems GmbH from early 2017 through November 2021; biochemistry and molecular biology graduating with a BA from Rice University in 1983